Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
Alopecia areata is an autoimmune condition characterized by...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
The creatinine level was 2.6 mg per deciliter (230 μmol per...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Given the wide availability and low cost of ivermectin and...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
14 gru 2022 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients...
In cells infected by SARS-CoV-2, ivermectin has been shown to inhibit the attachment of the virus's spike protein to the human cell membrane, which was able to reduce the viral RNA concentration by almost 5000-fold, what increased hopes for clinical benefit in prevention and treatment of COVID-19 [10, 13, 14].
Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.
13 cze 2022 · Ivermectin did not have any significant effect on outcomes of COVID-19 patients and as WHO recommends, use of ivermectin should be limited to clinical trials. Introduction. In December 2019, a cluster of cases of pneumonia with unknown etiology was reported in Wuhan, China [1].
This study was designed to test the hypothesis that exposure to ivermectin in early disease prevents mortality due to COVID-19. A secondary objective was to see if the drug has any impact on the length of hospital stay among the survivors.
People being treated with ivermectin had to have laboratory-test confirmed COVID-19 and be receiving treatment in hospital or as outpatients. We compared and summarized the results of the studies and rated our confidence in the evidence, based on common criteria as to how reliable the evidence is.
